Nomogram for the personalisation of radiotherapy treatments in breast cancer patients.

INTRODUCTION: Numerous prospective studies have shown that the incorporation of genomic assays into clinical practice significantly impacts the choice of adjuvant treatments for patients with early-stage breast cancer. However, the same evidence does not exist for the treatment of locoregional recurrences. HYPOTHESIS AND OBJECTIVES: The main objective of this work was to identify the clinicopathological, molecular, and genetic parameters that allow patients to be more precisely categorised into risk groups, in order to create a locoregional recurrence riskclassification tool, the PersonalRT27. MATERIAL AND METHODS: To create PersonalRT27, we retrospective assessed the variables of patients with early breast cancer (stages I or II) who had undergone the OncotypeDx ® and MammaPrint ® genetic tests. These variables and factors included in the tests were categorised and weighted to obtain scores between 1 and 5 pointsto represent a lower or higher risk of relapse, respectively, based on these factors and as determined by the researchers. RESULTS: The mean follow-up time was 60.5 months (range 25-96 months); locoregional progression-free survival at the time of the analysis was 98.4%, and overall survival was 97.5%, of which 0.6% of the deaths had been cancer specific. The area under the curve for the PersonalRT27 was 0.76 (95% CI [0.70, 0.81]), sensitivity was 78%, and the specificity was 58.9%. We used these factors to create an inhospital web-based nomogram. CONCLUSIONS: The PersonalRT27 is a novel tool that integrates clinical-pathological, molecular, and genetic parameters. External and independent validation will be required to implement its clinical use.

Tratamiento conservador del cáncer de mama y factores pronósticos de recidiva local / Conservative treatment of invasive breast cancer and prognostic factors of local recurrence

Introducción Actualmente, la cirugía conservadora seguida de radioterapia es el tratamiento de elección para los estadios tempranos de cáncer de mama ya que ha demostrado ser equivalente a la mastectomía en cuanto a la sobrevida. Sin embargo, la posibilidad de recidiva local luego del tratamiento conservador existe, y se han descripto diferentes factores pronósticos vinculados a ella. Objetivos Estimar la tasa de recidiva local en las pacientes con tratamiento quirúrgico conservador e identificar los parámetros relacionados con mayor riesgo de recidiva local de cáncer de mama. Material y método Se analizaron en forma retrospectiva y comparativa 450 pacientes operadas con cirugía conservadora con diagnóstico de cáncer de mama invasor, intervenidas entre enero de 2006 y diciembre de 2012. Se evaluaron las siguientes variables para recidiva local: edad, estado menopáusico, tamaño tumoral, tipo histológico, grado histológico, compromiso axilar, invasión linfovascular, componente intraductal extenso, receptores hormonales, her2, márgenes y multifocalidad. Resultados Con un seguimiento medio de 71,2 meses, la tasa de recidiva fue del 6,2% (28 de 450). El tiempo medio hasta la recidiva fue de 53 meses. En el análisis univariado, la edad menor a 35 años (p=0,0008), el estado premenopáusico (p=0,036), el tamaño tumoral mayor a 1 cm (p=0,04), el compromiso axilar (p=0,008), la invasión linfovascular (p=0,033) y el componente intraductal extenso (p=0,007) mostraron estar asociados a un mayor riesgo de recidiva local. En cambio, el tipo y grado histológico, los receptores hormonales, el her2, los márgenes y la multifocalidad no tuvieron relevancia en el desarrollo de la misma. Conclusiones Mediante este estudio, pudimos observar que la edad joven, la premenopausia, el tamaño tumoral, la enfermedad axilar y la presencia de invasión linfovascular y componente intraductal extenso en el tumor representan factores pronósticos de recidiva de cáncer de mama luego del tratamiento quirúrgico conservador.

Introduction Nowadays, breast conserving surgery followed by radiation therapy is the treatment of choice for early stage breast cancer, since it has proven to be equivalent to mastectomy in terms of survival. However, there is a possibility of recurrence after conservative treatment and there are different prognostic factor associated with it. Objectives To estimate the rate of local recurrence in patients with conservative treatment and identify the parameters related to the higher risk of breast cancer local recurrence. Materials and method Four hundred and fifty (450) patients operated on conservative surgery, between January 2006 and December 2012, with diagnose of invasive breast cancer, have been analyzed in a retrospective a comparative way. The following risk variables have been evaluated for local recurrence: age, menopausal status, tumor size, histologic type, histologic grade, nodal status, lymphovascular invasion, extensive intraductal component, hormone receptors, her2, margins status and multifocal tumors. Results For an average follow up of 72.2 months, the average rate of recurrence was 6.2% (28/450). The average relapse time was 53 months. On the univariate analysis, age lower than 35 years (p=0.0008), premenopausal status (p=0.036), tumor size larger than 1 cm (p=0.04), nodal status (p=0.008), lymphovascular invasion presence (p=0.033) and the extensive intraductal component presence (p=0.007) have shown to be associated with higher risk for local recurrence. On the other hand, histological type and grade, hormone receptors, her2, margin status and multifocal tumors had no relevance for development of local recurrence. Conclusions Through this study we were able to observe that young age, premenopausal, tumor size, nodal status, lymphovascular invasion presence, extensive intraductal component presence are indicators of an increased risk of local recurrence after conservative treatment.